BE875475A - Iminoquinazolines - Google Patents

Iminoquinazolines

Info

Publication number
BE875475A
BE875475A BE0/194524A BE194524A BE875475A BE 875475 A BE875475 A BE 875475A BE 0/194524 A BE0/194524 A BE 0/194524A BE 194524 A BE194524 A BE 194524A BE 875475 A BE875475 A BE 875475A
Authority
BE
Belgium
Prior art keywords
iminoquinazolines
Prior art date
Application number
BE0/194524A
Other languages
English (en)
Inventor
W Beverung
R Partyka
T Jenks
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of BE875475A publication Critical patent/BE875475A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
BE0/194524A 1978-04-10 1979-04-10 Iminoquinazolines BE875475A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/894,464 US4146718A (en) 1978-04-10 1978-04-10 Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides

Publications (1)

Publication Number Publication Date
BE875475A true BE875475A (fr) 1979-10-10

Family

ID=25403115

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/194524A BE875475A (fr) 1978-04-10 1979-04-10 Iminoquinazolines

Country Status (19)

Country Link
US (1) US4146718A (fr)
JP (2) JPS54135794A (fr)
AU (1) AU527748B2 (fr)
BE (1) BE875475A (fr)
CA (1) CA1109067A (fr)
CH (1) CH639079A5 (fr)
DE (1) DE2914494A1 (fr)
DK (1) DK156062C (fr)
FI (1) FI66616C (fr)
FR (1) FR2422649A1 (fr)
GB (1) GB2018765B (fr)
GR (1) GR72937B (fr)
HU (2) HU179424B (fr)
IE (1) IE48150B1 (fr)
NL (1) NL191182C (fr)
SE (2) SE445217B (fr)
SU (1) SU1120923A3 (fr)
YU (1) YU40554B (fr)
ZA (1) ZA791727B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1131631A (fr) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Derives de la quinazoline et preparations pharmaceutiques
US4818273A (en) * 1983-11-14 1989-04-04 The Dow Chemical Company Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
JPH05271200A (ja) * 1991-05-22 1993-10-19 Egyt Gyogyszervegyeszeti Gyar ６，７−ジクロロ−１，５−ジヒドロ−イミダゾ〔２，１−ｂ〕キナゾリン−２〔３Ｈ〕−オンの製造方法
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
CA2171073A1 (fr) * 1995-12-04 1997-06-05 Philip C. Lang Methode de preparation d'ethyl-n-(2,3-dichloro-6-nitrobenzyl)glycine
CA2238283C (fr) 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
WO2001021163A2 (fr) * 1999-09-21 2001-03-29 Emory University Procedes et compositions pour le traitement de troubles lies aux plaquettes au moyen d'agents inhibiteurs de trajet de mpl
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
PL377933A1 (pl) * 2003-01-23 2006-02-20 Shire Holdings Ag Formulacja i sposoby leczenia trombocytemii
AT412873B (de) * 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2026813A2 (fr) 2006-05-09 2009-02-25 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
AU2008212668B2 (en) * 2007-02-06 2013-02-07 Cipla Limited Process for the preparation of ethyl-N-(2, 3-dichloro-6-nitrobenzyl) glycine hydrochloride
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808951D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808953D0 (en) 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201004491D0 (en) 2010-03-18 2010-05-05 Shire Llc Quinazoline analogues
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014111444A1 (fr) * 2013-01-18 2014-07-24 Synthon B.V. Forme cristalline de type ii de monohydrate d'anagrélide hydrochloride
EP2981537B1 (fr) * 2013-03-14 2017-05-10 Synthon B.V. Procédé de préparation d'anagrélide
WO2014206484A1 (fr) 2013-06-28 2014-12-31 Synthon B.V. Procédé de préparation d'anagrélide
CN106854162A (zh) * 2016-12-13 2017-06-16 浙江海正化工股份有限公司 一种2,3‑二氯‑6‑硝基苯胺及其制备方法
CN107903217B (zh) * 2017-11-16 2021-11-23 湖北省宏源药业科技股份有限公司 一种阿那格雷杂质b的制备方法
WO2020061284A1 (fr) 2018-09-19 2020-03-26 Modernatx, Inc. Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794964A (fr) * 1972-02-04 1973-08-02 Bristol Myers Co Nouveaux agents hypotenseurs et procede pour les preparer
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.

Also Published As

Publication number Publication date
SE8404061D0 (sv) 1984-08-10
DE2914494A1 (de) 1979-10-18
GB2018765A (en) 1979-10-24
DK144779A (da) 1979-10-11
IE48150B1 (en) 1984-10-17
SE454990B (sv) 1988-06-13
HU179424B (en) 1982-10-28
JPH0222276A (ja) 1990-01-25
DK156062C (da) 1989-11-06
SE445217B (sv) 1986-06-09
IE790753L (en) 1979-10-10
FI66616B (fi) 1984-07-31
NL191182B (nl) 1994-10-03
FI791125A (fi) 1979-10-11
FR2422649B1 (fr) 1983-07-29
CA1109067A (fr) 1981-09-15
JPH0233035B2 (fr) 1990-07-25
DK156062B (da) 1989-06-19
NL7902825A (nl) 1979-10-12
NL191182C (nl) 1995-03-01
HU187562B (en) 1986-01-28
YU83079A (en) 1983-12-31
JPS54135794A (en) 1979-10-22
JPH0312066B2 (fr) 1991-02-19
CH639079A5 (de) 1983-10-31
ZA791727B (en) 1980-05-28
SU1120923A3 (ru) 1984-10-23
SE8404061L (sv) 1984-08-10
FR2422649A1 (fr) 1979-11-09
GR72937B (fr) 1984-01-13
SE7903198L (sv) 1979-10-11
US4146718A (en) 1979-03-27
AU4588979A (en) 1979-10-18
AU527748B2 (en) 1983-03-24
YU40554B (en) 1986-02-28
FI66616C (fi) 1984-11-12
GB2018765B (en) 1982-08-04
DE2914494C2 (fr) 1989-07-20

Similar Documents

Publication Publication Date Title
AT379079B (de) Akupunkturgeraet
AT370950B (de) Hoeschenwindel
FI791125A (fi) Iminokinazoliner
AT365922B (de) Netzbett
BE876254A (fr) Omsluitingsinrichting
BE874159A (fr) Thermoplongeur
BE876344A (fr) Snelkoppelend kogelscharnier
FI780210A (fi) Anordning foer snoevallkontrollskaermar foer snoeplogar
AT374352B (de) Sportschuh
BE876059A (fr) Azolopyrimidinones
BE873461A (fr) Kleerhanger
AR218561A1 (es) Copoliester p-oxibenzoilico
BE877468A (fr) Recolteuse-hacheuse
BE875799A (fr) N-alkenylmoranolines
ATA26879A (de) B-ettbank
AT368010B (de) Rollskier
BE877875A (fr) Automobielwiel
FI792266A (fi) Broms
AT355471B (de) Schipresse
AR224881A1 (es) 2-hidroxifenilbenzotiazoles
ATA562378A (de) Handgranate
AT361359B (de) Skistock
AT357332B (de) Fraeser
AT376331B (de) Umpolmodulator
BE869882A (fr) Vibropuncteur

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: BRISTOL-MYERS CY

Effective date: 19990410